Core Viewpoint - The National Healthcare Security Administration (NHSA) has initiated a crackdown on "shadow pharmacists" in retail pharmacies, following the release of an announcement that highlights the prevalence of fraudulent practices involving pharmacists' credentials [1][2]. Group 1: Regulatory Actions - The NHSA has conducted a review of medical insurance settlement data from retail pharmacies since April, identifying instances where pharmacists' names appear across multiple pharmacies, indicating potential credential fraud or "hanging certificates" [1][2]. - The announcement outlines that the NHSA will employ various methods, including routine inspections, special checks, and data analysis, to monitor the compliance of pharmacists in retail pharmacies [2][5]. - A total of 24 provinces, nearly 24,000 retail pharmacies, and approximately 9,500 pharmacists are involved in the investigation of credential fraud [2][3]. Group 2: Compliance Requirements - Retail pharmacies are required to have at least one licensed pharmacist on staff, who must be registered at the pharmacy's location and provide continuous pharmaceutical services [2][5]. - The NHSA has mandated that pharmacists conduct self-checks and report any unauthorized use of their credentials to local healthcare authorities [4][5]. Group 3: Findings and Statistics - The investigation revealed three main types of violations: cross-province practices, inter-city practices, and intra-city practices, affecting thousands of pharmacies and pharmacists across multiple provinces [3]. - Notably, 293 pharmacists were found to have credentials associated with over 10 pharmacies, with one pharmacist linked to as many as 198 pharmacies [3][6]. Group 4: Future Directions - The NHSA is expected to intensify its enforcement efforts as the transition period for the "differentiated pharmacist allocation" policy approaches its conclusion in 2025 [6][7]. - The use of advanced technologies such as 5G and big data is being encouraged to enhance the monitoring of pharmacists' compliance and improve the quality of pharmaceutical services [7].

5月28日，国家医保局公布定点零售药店药师涉嫌"挂证"情况。记者查阅发现，此次公布的出现在 多家定点零售药店药品费用明细中的药师超过9000人，近300人涉嫌"挂证"的药店数达到两位数，6人涉 嫌在百家以上药店"挂证"，其中疑似"挂证"机构数最多的药师疑似在198家机构"挂证"。 2021年2月1日起施行的《零售药店医疗保障定点管理暂行办法》规定，定点零售药店应至少配备1 名取得执业药师资格证书或具有药学、临床药学、中药学专业技术资格证书的药师，且注册地在该定点 零售药店所在地。 国家医保局对疑似"挂证"情况进行了分类统计，135名药师疑似跨省份"挂证"，792名药师疑似本省 份跨市"挂证"，8583名药师疑似同地市跨机构"挂证"。其中疑似"挂证"机构数最多的药师所在省份为湖 南，疑似"挂证"机构数达到198家。 国家医保局要求，相关药师立即开展自查，如在不知情情况下，被定点零售药店假冒信息或"挂 证"的，要及时收集相关材料，主动联系当地医保部门说明情况，坚决杜绝"挂证"行为。 为核查相关信息，保障参保人用药安全和医保基金安全，维护正规注册药师合法权益，国家医保局 要求相关定点零售药店全面检查本单位药师配备、 ...

近期，国家医保局对全国定点零售药店4月份以来的医保结算数据进行了筛查分析发现，部分药师姓名 (对应同一身份证号)出现在多家定点零售药店的药品费用明细中，可能存在药师信息被假冒或药师"挂 证"的违规情况。这既威胁了人民群众用药安全和医保基金安全，也损害了正规注册药师的合法权益， 共涉及24个省份、23997家定点零售药店、9563名药师。针对这种情况，国家医保局28日发布公告，要 求对定点零售药店药师"挂证"等情况开展核查，以维护人民群众用药安全、维护医保基金安全、维护广 大注册药师合法权益。(人民日报) ...

Group 1 - The pharmaceutical sector has experienced a nearly five-year correction since a strong rally from 2019 to 2020, but investment is gradually warming up this year driven by innovative drug concepts [1] - Wan Minyuan, a fund manager with a medical background, believes that the most difficult times for the pharmaceutical industry may have passed, with a relatively optimistic outlook on the sector's performance [1][4] - The investment strategy of Wan Minyuan emphasizes safety and a contrarian approach, focusing on buying when the market is less interested and selling when it is more enthusiastic [2][3] Group 2 - Wan Minyuan's investment philosophy is rooted in maintaining a high win rate by ensuring correct decisions outweigh incorrect ones, which is crucial for sustainable and predictable returns [2][3] - The pharmaceutical sector is expected to see improvements in 2025 due to the gradual resolution of multiple factors that have constrained its performance, including favorable policy changes [4][5] - Key drivers for long-term growth in the pharmaceutical industry remain unchanged, such as population aging, changes in disease patterns, and the supply of innovative technologies [5] Group 3 - Wan Minyuan focuses on companies with stable operations and emphasizes the importance of prudent financial management, avoiding overly aggressive accounting practices [3][5] - The investment strategy includes a long holding period for core positions, with a disciplined approach to selling based on specific criteria such as valuation bubbles and significant deviations from expected company performance [5][6] - Wan Minyuan identifies three main investment opportunities in the pharmaceutical sector: innovative drugs and medical devices, recovery in pharmaceutical consumption, and low price-to-book ratio assets [6][7] Group 4 - The interest in innovative drugs is growing, with an increase in upfront payments for licensing deals, although A-share market valuations for innovative drugs are currently high [7] - Wan Minyuan is also expanding investment horizons beyond the pharmaceutical sector, looking at domestic demand and technology sectors, particularly in undervalued assets in the Hong Kong market [7]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail pharmacy sector has passed its low point and is gradually entering an industry consolidation phase, with performance recovery underway. The pressure on small and medium-sized pharmacies is increasing, leading to a rise in concentration among leading enterprises, supported by potential growth from policy recovery [4][10] - The pharmaceutical distribution market is expanding, and industry concentration is expected to increase, with a focus on improving the operational quality of leading companies. The implementation of the two-invoice system is shortening the drug distribution chain, benefiting leading enterprises with upstream and downstream resource advantages [4][10] Summary by Sections Retail Pharmacies - The number of retail pharmacies in China showed negative growth in Q4 2024, marking a turning point as the industry enters a "market consolidation phase." The number of closed pharmacies in 2024 was 6,778 in Q1, 8,791 in Q2, 9,545 in Q3, and 14,114 in Q4, with net additions of 9,257, 6,322, 2,847, and -3,395 respectively [10][11] - The performance of retail pharmacies is expected to stabilize and recover due to improved compliance operations and refined management practices, alongside seasonal disease outbreaks and new pricing policies [4][11] - Policies supporting the inclusion of retail pharmacies in outpatient management are expected to enhance their role in the healthcare system, facilitating prescription flow and increasing foot traffic to physical pharmacies [4][10][11] Pharmaceutical Distribution - The pharmaceutical distribution market is expected to grow, with leading companies benefiting from scale and operational quality improvements. The "4+N" competitive landscape is deepening, and the market size is expanding due to increased shares of retail pharmacies and grassroots medical terminals [4][10] - The use of AI technology and CSO services is expected to enhance the competitive edge of leading companies, reinforcing the trend of "the strong getting stronger" [4][10] Recommended and Beneficiary Stocks - Recommended stocks include Yifeng Pharmacy, Lao Bai Xing, and Jian Zhi Jia, while beneficiary stocks include Da Shen Lin, Yi Xin Tang, and Shu Yu Ping Min [4][15]

Core Viewpoint - MSCI announced its quarterly index adjustments for May 2025, adding 30 stocks to its global standard index, including five A-shares: Chipone Technology, Baillie Gifford, Huatai Medical, Light Media, and Haizhi Science [1][4][7]. Group 1: MSCI Index Adjustments - MSCI's May adjustments included the addition of 30 stocks and the removal of 61 stocks from its global standard index [6]. - The largest new additions to the MSCI global standard index by market capitalization include Ryanair Holdings, Sigma Healthcare, and International Airlines Group [6]. - The MSCI Emerging Markets Index added three major stocks: ADNOC Gas, Dubai Electricity & Water Authority, and Baillie Gifford [6]. Group 2: A-Share Specifics - In the MSCI China A-share index, five stocks were added: Chipone Technology, Baillie Gifford, Huatai Medical, Light Media, and Haizhi Science, while 15 stocks were removed, including Hisense Home Appliances and FAW Jiefang [7][9]. - Additionally, one Hong Kong stock, Chongqing Rural Commercial Bank, was added, while Shanghai Pharmaceuticals and COSCO Shipping Energy were removed [8]. Group 3: Market Reactions - The U.S. stock market showed mixed results, with the Dow Jones down 0.64%, the S&P 500 up 0.72%, and the Nasdaq up 1.61%, driven by strong performance in chip stocks [2][12]. - Nvidia's stock surged by 5.63%, contributing significantly to the Nasdaq's rise, while AMD also saw a 4.01% increase [2][14]. - AMD announced a strategic partnership with Humain worth $10 billion to advance global artificial intelligence, indicating strong growth potential in the semiconductor sector [15].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The report emphasizes the focus on innovative drugs and the recovery of consumer demand as key drivers for investment in the pharmaceutical sector [3] - The TCE (T-cell Engager) solid tumor pipeline is highlighted, with Janux and Vir making significant progress in their development plans [5][13] - The pharmaceutical sector saw a 1.01% increase in the second week of May, underperforming the CSI 300 index by 1 percentage point, ranking 26th among 31 sub-industries [6][15] Summary by Sections TCE Solid Tumor Pipeline Update - Janux announced that JANX007 (PSMA/CD3) will enter the 1b expansion trial, targeting taxane-naive patients, marking a significant step for TCE in solid tumors [5][13] - Vir has registered VIR-5525 (EGFR/CD3) for a first-in-human trial, expected to start this month, focusing on EGFR-expressing NSCLC [5][13] Market Performance - In the second week of May, the pharmaceutical sector increased by 1.01%, with the medical device sector showing the highest growth at 1.98% [6][19] - The report notes that the offline pharmacy sector experienced the largest decline, dropping by 1.65% [19] Recommended and Benefiting Stocks - Recommended stocks in the pharmaceutical and biotechnology sector include: - Innovative drugs: Zai Lab, Innovent Biologics, and others [7] - Traditional Chinese medicine: Dong-E E-Jiao, Jiangzhong Pharmaceutical, and others [7] - Medical devices: Mindray Medical, and others [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The report emphasizes the focus on innovative drugs and the recovery of consumer demand as key drivers for investment in the pharmaceutical sector [3] - The TCE (T-cell Engager) solid tumor pipeline is highlighted, with Janux and Vir making significant progress in their development plans [5][13] - The pharmaceutical sector saw a 1.01% increase in the second week of May, underperforming the CSI 300 index by 1 percentage point, ranking 26th among 31 sub-industries [6][15] Summary by Sections TCE Solid Tumor Pipeline Update - Janux announced that JANX007 (PSMA/CD3) will enter the 1b expansion trial, targeting taxane-naive patients, marking a significant step for TCE in frontline indications [5][13] - Vir has registered VIR-5525 (EGFR/CD3) for a first-in-human trial, expected to start this month, focusing on EGFR-expressing NSCLC [5][13] Market Performance - In the second week of May, the pharmaceutical sector increased by 1.01%, with the medical device sector showing the highest growth at 1.98% [6][19] - The report notes that the offline pharmacy sector experienced the largest decline, dropping by 1.65% [19] Recommended and Benefiting Stocks - Recommended stocks in the pharmaceutical and biotechnology sector include: - Innovative drugs: Zai Lab, Innovent Biologics, Kelun-Biotech, Yifan Pharmaceutical, and others [7] - Traditional Chinese medicine: Dong-E E-Jiao, Jiangzhong Pharmaceutical, and others [7] - Medical devices: Mindray, Aohua Endoscopy, and others [7]

核心观点 4 月29 日，公司发布2024 年年度业绩报告，实现营业收入223.58亿元，同比-0.36%，实现归母净利润 5.19 亿元，同比下降44.13%，实现扣非归母净利润4.96 亿元，同比下降41.18%，实现基本每股收益0.68 元，业绩低于我们预期。展望2025 年，公司门店结构持续优化，火炬项目稳步落地，零售板块毛利率 有望持续改善，叠加公司持续落地降本增效举措，我们期待公司利润增速加速恢复。 事件 公司发布2024 年年度业绩报告，业绩低于我们预期4 月29 日，公司发布2024 年年报及2025 年一季报， 2024年实现营业收入、归母净利润及扣非归母净利润分别为223.58 亿元、5.19亿元及4.96亿元，分别同 比下降0.36%、44.13%及41.18%。 2024 年，公司营业收入同比下降0.36%，主要由于：1）公司24 年优化部分盈利能力较差的门店，零售 板块收入同比下降1.25%；2）行业竞争压力加剧，部分老店增长放缓，但公司加盟、联盟及分销业务 增长5.92%为31.05 亿元，较为稳健。归母净利润同比下降44.13%，扣非归母净利润同比下降41.18%， 慢于收入增长 ...

健之佳（605266）公告，2025年第一季度营业收入22.94亿元，同比下降0.85%。归属于上市公司股东的 净利润3352.56万元，同比下降35.85%。基本每股收益0.22元/股，同比下降35.29%。 ...